Blood Vessels, Thrombosis & Hemostasis最新文献_第4页

Is interrupting anticoagulation for thrombosis risk stratification safe? 为进行血栓风险分层而中断抗凝治疗安全吗？

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-23 DOI: 10.1016/j.bvth.2024.100028

Abhinav Mathur , Alexis Cairns , Henry G. Watson , Mohammed M. Khan

引用次数: 0

Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan 日本批准埃米珠单抗前后获得性 A 型血友病的临床特征和治疗结果

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-16 DOI: 10.1016/j.bvth.2024.100027

Daichi Kishi , Masashi Nishikubo , Yoshimitsu Shimomura , Takayuki Ishikawa , Tadakazu Kondo

{"title":"Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan","authors":"Daichi Kishi , Masashi Nishikubo , Yoshimitsu Shimomura , Takayuki Ishikawa , Tadakazu Kondo","doi":"10.1016/j.bvth.2024.100027","DOIUrl":"10.1016/j.bvth.2024.100027","url":null,"abstract":"<div><h3>Abstract</h3><div>Acquired hemophilia A (AHA) is a rare and potentially fatal bleeding disorder. Although bypassing agents effectively control active bleeding, their disadvantages, such as high cost and frequent administration, necessitate an agent that prevents recurrent bleeding events requiring bypassing agents. Emicizumab, a recombinant, humanized, bispecific monoclonal antibody with coagulation factor VIII (FVIII)–mimetic activity, was approved in Japan in 2022 for preventing bleeding in patients with AHA. However, owing to the rarity of the disease, real-world data on emicizumab use in AHA are scarce. Therefore, we aimed to assess the clinical characteristics and outcomes of 19 patients who were newly diagnosed with AHA before (non-emicizumab group [non-emi group], n = 12) and after (emicizumab group [emi group], n = 7) emicizumab approval in Japan. The median age, FVIII coagulation activity, and FVIII inhibitor titer were 81 vs 76 years, 1.0% vs 1.0%, and 43.75 vs 622 Bethesda units per mL in the non-emi and emi groups, respectively. Severe bleeding occurred in 14% of patients in the emi group, compared with 58% of patients in the non-emi group. Additionally, the doses of bypassing agents per patient were 43.4 vs 7, and the units of red blood cell transfusion per patient were 26.7 vs 4 in the non-emi and emi groups, respectively. Their hospital stays were median 73.5 days and 44 days, respectively. All patients treated with emicizumab maintained their activities of daily living (ADLs) and experienced no side effects. This study suggests that emicizumab effectively prevents bleeding in patients with AHA. Moreover, emicizumab may lead to shorter hospital stays, maintained ADLs, reduced costs, and improved prognosis in patients with AHA.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100027"},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142535293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures 骨髓增生性肿瘤患者的围手术期疗效：对 354 例手术的多中心分析

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-16 DOI: 10.1016/j.bvth.2024.100026

Natasha Szuber , Harold J. Olney , Steve Dagenais Bellefeuille , Mégane Tanguay , Awatef Shehabeldeen , Saima Ahmed , Michaël Harnois , Jaroslav Prchal , Lambert Busque , Shireen Sirhan

引用次数: 0

Trauma-induced dysfibrinogenemia: the von Clauss assay does not accurately measure fibrinogen levels after injury 创伤诱发的纤维蛋白原不良血症：冯克劳斯测定法不能准确测量受伤后的纤维蛋白原水平

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-09-01 DOI: 10.1016/j.bvth.2024.100017

Margot DeBot , Christopher Erickson , Terry Schaid , Ian LaCroix , Ernest E. Moore , Christopher Silliman , Mitchell J. Cohen , Angelo D’Alessandro , Kirk C. Hansen

{"title":"Trauma-induced dysfibrinogenemia: the von Clauss assay does not accurately measure fibrinogen levels after injury","authors":"Margot DeBot , Christopher Erickson , Terry Schaid , Ian LaCroix , Ernest E. Moore , Christopher Silliman , Mitchell J. Cohen , Angelo D’Alessandro , Kirk C. Hansen","doi":"10.1016/j.bvth.2024.100017","DOIUrl":"10.1016/j.bvth.2024.100017","url":null,"abstract":"<div><h3>Abstract</h3><p>Trauma patients who sustain severe tissue injury and hemorrhage often receive fibrinogen repletion to avert coagulopathy and achieve hemostasis. However, fibrinogen supplementation has not shown a benefit in trauma patients with coagulopathy. The von Clauss functional fibrinogen assay is the primary indication for fibrinogen transfusion. This assay, however, infers fibrinogen levels optically via in vitro clot formation time and does not directly measure the quantity or quality of plasma fibrinogen. We hypothesized that the Clauss fibrinogen activity assay does not accurately reflect true fibrinogen levels in severely injured patients. Here, we demonstrate normal baseline plasma fibrinogen levels as measured by mass spectrometry despite coagulopathic Clauss values in severely injured patients. This discrepancy is most significant in patients with coagulopathy (international normalized ratio of >1.3) or with high shock, and persists even after fibrinogen repletion. These data highlight the need to reevaluate clinical testing of fibrinogen activity and transfusion criteria for the critically injured, and indicate that correcting shock and the oxidative, inflammatory milieu of trauma may be more effective at improving fibrinogen activity. This trial was registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT01838863.</p></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 3","pages":"Article 100017"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950327224000172/pdfft?md5=5880916926772cd8bc0dccf15d720b5a&pid=1-s2.0-S2950327224000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141706753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy EASIX和m-EASIX可预测CAR T细胞疗法后的严重细胞因子释放综合征和总生存率

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-08-21 DOI: 10.1016/j.bvth.2024.100025

Eleni Gavriilaki , Ifigeneia Tzannou , Ioannis Batsis , Ioannis Tsonis , Maria Liga , Konstantinos Gkirkas , Maria Ximeri , Panagiotis Dolgyras , Vasiliki Bampali , Paschalis Evangelidis , Zoi Bousiou , Anna Vardi , Christos Demosthenous , Eulampia Stroggyli , Maria Bouzani , Eleftheria Sagiadinou , Despina Mallouri , Tatiana Tzenou , Damianos Sotiropoulos , Stavros Gigantes , Ioannis Baltadakis

引用次数: 0

Rising total leukocyte counts correspond with rising platelet counts in thrombotic thrombocytopenic purpura 血栓性血小板减少性紫癜患者的白细胞总数上升与血小板计数上升相对应

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-08-21 DOI: 10.1016/j.bvth.2024.100024

Noelle I. Samia , Thomas J. Raife

{"title":"Rising total leukocyte counts correspond with rising platelet counts in thrombotic thrombocytopenic purpura","authors":"Noelle I. Samia , Thomas J. Raife","doi":"10.1016/j.bvth.2024.100024","DOIUrl":"10.1016/j.bvth.2024.100024","url":null,"abstract":"<div><h3>Abstract</h3><div>Thrombotic thrombocytopenic purpura (TTP) is a rare disorder involving pathological platelet–von Willebrand factor interaction, resulting in microvascular thrombosis. The consumption of platelets in TTP microthrombi results in severe thrombocytopenia which resolves with resolution of the microvascular thrombosis. Over the course of treatment, patient platelet counts often rise and fall multiple times before stable remission is achieved. On casual inspection, we noted that total leukocyte counts follow a pattern that appears to correspond to platelet counts. To explore whether changing leukocyte counts track significantly with changing platelet counts, we examined paired daily platelet counts and total leukocyte counts in 27 episodes of TTP in 13 patients across 2 institutions comprising 423 days of data. We modeled the nonlinear behavior in the data using a threshold mixed-effects regression model, in which we found a significant temporal relationship between total leukocyte counts and platelet counts. The model proved that, on a day when platelet counts were rising in previous days, the total leukocyte count is predictive of the rise in platelet count. The higher the total leukocyte count, the greater the rise in platelet count. Our results support the hypothesis that leukocytes play a role in the resolution of TTP microvascular thrombosis.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100024"},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of vitamin C with Fe supplementation in patients with iron deficiency anemia: a systematic review and meta-analysis 缺铁性贫血患者补充维生素 C 和铁的疗效：系统回顾和荟萃分析

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-08-02 DOI: 10.1016/j.bvth.2024.100023

Joanna Deng ∗ , Luca Ramelli ∗ , Pei Ye Li , Ali Eshaghpour , Allen Li , Giovanna Schuenemann , Mark A. Crowther

{"title":"Efficacy of vitamin C with Fe supplementation in patients with iron deficiency anemia: a systematic review and meta-analysis","authors":"Joanna Deng ∗ , Luca Ramelli ∗ , Pei Ye Li , Ali Eshaghpour , Allen Li , Giovanna Schuenemann , Mark A. Crowther","doi":"10.1016/j.bvth.2024.100023","DOIUrl":"10.1016/j.bvth.2024.100023","url":null,"abstract":"<div><h3>Abstract</h3><div>Oral iron (Fe) supplementation is one of the mainstays of treatment for iron deficiency anemia (IDA). However, its therapeutic effects are limited when there is poor absorption from the gastrointestinal tract. Vitamin C is hypothesized to improve uptake when combined as an adjunct agent. We aimed to determine the difference in hematologic outcomes in patients with IDA receiving oral iron, with or without vitamin C. MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials were searched from database inception to July 2023 for studies investigating the use of oral iron supplements with vitamin C in patients with IDA. The primary outcome was the change in serum hemoglobin (Hb). Secondary outcomes include change in serum ferritin, reticulocyte percentage, and incidence of adverse events. A total of 2231 studies were retrieved; 10 randomized control trials (n = 1782), and 1 prospective cohort study (n = 148) comprising 1930 patients were included. Vitamin C supplementation was associated with a significant increase in serum Hb level (mean differences [MDs], 0.14 g/dL; 95% confidence interval [CI], 0.08-0.20; <em>P</em> < .01; 10 studies, 1490 patients) and serum ferritin levels (MD, 3.23 μg/L; 95% CI, 1.63-4.84; <em>P</em> < .01; 9 studies, 1682 patients) in the iron plus vitamin C group compared with the iron-only group. The addition of vitamin C to iron supplementation was associated with a small and likely clinically insignificant increase in serum Hb. The results of this study do not support routine supplementation of oral iron therapy with vitamin C in the treatment of IDA.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100023"},"PeriodicalIF":0.0,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142420675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges with measuring tissue factor antigen and activity in human plasma 测量人血浆中组织因子抗原和活性的挑战

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-07-31 DOI: 10.1016/j.bvth.2024.100022

Nigel Mackman , Ana T. A. Sachetto

{"title":"Challenges with measuring tissue factor antigen and activity in human plasma","authors":"Nigel Mackman , Ana T. A. Sachetto","doi":"10.1016/j.bvth.2024.100022","DOIUrl":"10.1016/j.bvth.2024.100022","url":null,"abstract":"<div><h3>Abstract</h3><div>Tissue factor (TF) is a transmembrane protein that, in association with its ligand factor VII (FVII)/activated factor VII (FVIIa), activates blood coagulation. TF is highly procoagulant and even very small amounts can activate blood coagulation. Levels of TF–positive extracellular vesicles (EVs) are increased in blood in diseases associated with thrombosis. However, it is challenging to accurately quantify the very low levels of TF in blood. Activity-based assays have higher sensitivity and specificity than antigen-based assays. Many anti-human TF antibodies have been generated but they differ in their affinity for TF and bind to different epitopes. They can be divided into 2 groups: those that compete with FVII/FVIIa binding to TF, and those that bind to both TF and the TF-FVII/VIIa complex. Commercial enzyme-linked immunosorbent assays are commonly used to measure TF antigen in plasma but have low sensitivity and specificity for the detection of TF antigen in plasma. Flow cytometry is used to measure TF antigen on EVs but also has low sensitivity and specificity. Functional TF activity assays should be performed in the presence and absence of an inhibitory anti-TF antibody to distinguish between TF-dependent and TF-independent FXa generation because FVIIa can activate FX in the absence of TF. TF pathway inhibitor inhibits the TF-FVIIa complex and reduces TF activity of isolated EVs. Two commercial assays are available for the measurement of TF activity of EVs isolated from human plasma. Measurement of TF activity of EVs isolated from plasma may be a useful biomarker of thrombotic risk in different diseases.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100022"},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142326630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A 严重血友病 A 患儿的区域脑容量及其与神经认知结果的关系

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-07-26 DOI: 10.1016/j.bvth.2024.100021

Silvia Verhofste , Ahmad Al-Huniti , Marci Novak , Amy L. Conrad , Ellen van der Plas , Lyndsay Harshman , Janice M. Staber

{"title":"Regional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A","authors":"Silvia Verhofste , Ahmad Al-Huniti , Marci Novak , Amy L. Conrad , Ellen van der Plas , Lyndsay Harshman , Janice M. Staber","doi":"10.1016/j.bvth.2024.100021","DOIUrl":"10.1016/j.bvth.2024.100021","url":null,"abstract":"<div><h3>Abstract</h3><div>The effect of factor VIII (FVIII) deficiency on neurocognitive outcomes in children with hemophilia A (HA) is not well characterized. This study aimed to examine differences in brain volume and neurocognition between children with severe HA and healthy controls.This single-center study included 32 males aged 6 to 16 years, 9 with severe FVIII deficiency and 23 healthy controls. Volumetric data from magnetic resonance imaging and neurocognitive testing were compared using linear models including age to evaluate the association between regional brain volume and function. Cerebellar gray matter volume was significantly smaller in the HA cohort than in healthy controls (estimate, –0.375; 95% confidence interval [CI], –0.732 to –0.019; t<sub>(26)</sub> = 2.07; <em>P</em> = .049). A reduction in cerebellar gray matter was associated with neurocognitive executive dysfunction as noted by abnormal scores on 2 executive function assessments: the Delis-Kaplan Executive Function System, total switching accuracy (estimate, 0.549; 95% CI, –0.876 to 0.221; t<sub>(25)</sub> = –3.28; <em>P</em> = .003) and total correct category switching (estimate, 0.538; 95% CI, –0.868 to 0.207; t<sub>(25)</sub> = –3.19; <em>P</em> = .004), and the Behavior Rating Inventory of Executive Function, behavioral regulation index score (estimate, 0.531; 95% CI, 0.228-0.835; t<sub>(25)</sub> = 3.44; <em>P</em> = .002). Our study provides key insights into the lower brain volumes found in patients with HA and the corresponding executive dysfunction. Quantitative brain volume assessment in patients with HA may provide an integrated measure and with further research could be a useful clinical tool when assessing risk for neurocognitive dysfunction.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 4","pages":"Article 100021"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202 血管生物标志物揭示了移植后环磷酰胺的独特毒性特征：对 BMT CTN 0402 和 1202 的二次分析

Blood Vessels, Thrombosis & Hemostasis Pub Date : 2024-07-26 DOI: 10.1016/j.bvth.2024.100020

Laura F. Newell , Najla El Jurdi , Brian C. Betts , Corey Cutler , Joseph H. Antin , John E. Levine , Angela Panoskaltsis-Mortari , Shernan G. Holtan

{"title":"Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202","authors":"Laura F. Newell , Najla El Jurdi , Brian C. Betts , Corey Cutler , Joseph H. Antin , John E. Levine , Angela Panoskaltsis-Mortari , Shernan G. Holtan","doi":"10.1016/j.bvth.2024.100020","DOIUrl":"10.1016/j.bvth.2024.100020","url":null,"abstract":"<div><h3>Abstract</h3><p>Posttransplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis regimens are associated with very low rates of severe acute and chronic GVHD after hematopoietic cell transplant (HCT). However, concerns about cardiac and other organ toxicities persist. This study aimed to compare the vascular biomarker profile of PTCy with other GVHD regimens, including tacrolimus/sirolimus (Tac/Sir) and tacrolimus/methotrexate (Tac/MTX), to generate hypotheses for toxicity mitigation strategies. Plasma samples from day +28 after transplant were analyzed against pretransplant baseline measurements in patients receiving PTCy-based GVHD prophylaxis as part of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1202 (n = 112) vs Tac/MTX (n = 98) and Tac/Sir (n = 95) regimens from BMT CTN 0402. Compared with Tac/MTX, PTCy was associated with increasing angiopoietin-2 levels and decreasing epidermal growth factor levels at day +28. In contrast, Tac/Sir displayed increasing follistatin and endoglin levels and decreasing vascular endothelial growth factor receptor 2 (VEGFR2) plasma levels after HCT. Across all cohorts, increasing epidermal growth factor was protective from nonrelapse mortality, and decreasing VEGFR2 was associated with subsequent development of extensive chronic GVHD. These distinct biomarker profiles offer insights that could guide strategies to mitigate unique GVHD prophylaxis–associated toxicities.</p></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"1 3","pages":"Article 100020"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950327224000202/pdfft?md5=01eb3abe1f0fcdbe3c0117bbf8ef11b8&pid=1-s2.0-S2950327224000202-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141850752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0